892 related articles for article (PubMed ID: 21606265)
1. Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging.
Kim JE; Kim SH; Lee SJ; Rhim H
AJR Am J Roentgenol; 2011 Jun; 196(6):W758-65. PubMed ID: 21606265
[TBL] [Abstract][Full Text] [Related]
2. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
Lee MH; Kim SH; Park MJ; Park CK; Rhim H
AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
[TBL] [Abstract][Full Text] [Related]
3. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
[TBL] [Abstract][Full Text] [Related]
4. Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC.
Kim YK; Lee WJ; Park MJ; Kim SH; Rhim H; Choi D
Radiology; 2012 Oct; 265(1):104-14. PubMed ID: 22891358
[TBL] [Abstract][Full Text] [Related]
5. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease.
Jang KM; Kim SH; Kim YK; Choi D
Acta Radiol; 2015 May; 56(5):526-35. PubMed ID: 24838304
[TBL] [Abstract][Full Text] [Related]
6. Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging.
Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
Radiology; 2014 Jun; 271(3):748-60. PubMed ID: 24588677
[TBL] [Abstract][Full Text] [Related]
7. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
Park MJ; Kim YK; Lee MH; Lee JH
Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
[TBL] [Abstract][Full Text] [Related]
8. Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis.
Kim AY; Kim YK; Lee MW; Park MJ; Hwang J; Lee MH; Lee JW
Acta Radiol; 2012 Oct; 53(8):830-8. PubMed ID: 22847903
[TBL] [Abstract][Full Text] [Related]
9. Newly developed hypervascular hepatocellular carcinoma during follow-up periods in patients with chronic liver disease: observation in serial gadoxetic acid-enhanced MRI.
Yamamoto A; Ito K; Tamada T; Higaki A; Kanki A; Sato T; Tanimoto D
AJR Am J Roentgenol; 2013 Jun; 200(6):1254-60. PubMed ID: 23701061
[TBL] [Abstract][Full Text] [Related]
10. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular carcinoma in North America: a multiinstitutional study of appearance on T1-weighted, T2-weighted, and serial gadolinium-enhanced gradient-echo images.
Kelekis NL; Semelka RC; Worawattanakul S; de Lange EE; Ascher SM; Ahn IO; Reinhold C; Remer EM; Brown JJ; Bis KG; Woosley JT; Mitchell DG
AJR Am J Roentgenol; 1998 Apr; 170(4):1005-13. PubMed ID: 9530051
[TBL] [Abstract][Full Text] [Related]
12. Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI.
Chong YS; Kim YK; Lee MW; Kim SH; Lee WJ; Rhim HC; Lee SJ
Clin Radiol; 2012 Aug; 67(8):766-73. PubMed ID: 22425613
[TBL] [Abstract][Full Text] [Related]
13. Detection of small hepatocellular carcinoma using gadoxetic acid-enhanced MRI: Is the addition of diffusion-weighted MRI at 3.0T beneficial?
Zhao XT; Li WX; Chai WM; Chen KM
J Dig Dis; 2014 Mar; 15(3):137-45. PubMed ID: 24354621
[TBL] [Abstract][Full Text] [Related]
14. Detection of liver malignancy with gadoxetic acid-enhanced MRI: is addition of diffusion-weighted MRI beneficial?
Kim YK; Kim CS; Han YM; Lee YH
Clin Radiol; 2011 Jun; 66(6):489-96. PubMed ID: 21367403
[TBL] [Abstract][Full Text] [Related]
15. Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma.
Hyodo T; Murakami T; Imai Y; Okada M; Hori M; Kagawa Y; Kogita S; Kumano S; Kudo M; Mochizuki T
Radiology; 2013 Feb; 266(2):480-90. PubMed ID: 23362095
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker.
Choi JW; Lee JM; Kim SJ; Yoon JH; Baek JH; Han JK; Choi BI
Radiology; 2013 Jun; 267(3):776-86. PubMed ID: 23401584
[TBL] [Abstract][Full Text] [Related]
18. Small hypervascular hepatocellular carcinoma: limited value of portal and delayed phases on dynamic magnetic resonance imaging.
Yu JS; Lee JH; Chung JJ; Kim JH; Kim KW
Acta Radiol; 2008 Sep; 49(7):735-43. PubMed ID: 18608015
[TBL] [Abstract][Full Text] [Related]
19. Value of gadoxetic acid-enhanced and diffusion-weighted MR imaging in evaluation of hepatocellular carcinomas with atypical enhancement pattern on contrast-enhanced multiphasic MDCT in patients with chronic liver disease.
Kim HS; Kim SH; Kang TW; Song KD; Choi D; Park CK
Eur J Radiol; 2015 Apr; 84(4):555-62. PubMed ID: 25617950
[TBL] [Abstract][Full Text] [Related]
20. Can the patient with cirrhosis be imaged for hepatocellular carcinoma without gadolinium?: Comparison of combined T2-weighted, T2*-weighted, and diffusion-weighted MRI with gadolinium-enhanced MRI using liver explantation standard.
Hardie AD; Kizziah MK; Rissing MS
J Comput Assist Tomogr; 2011; 35(6):711-5. PubMed ID: 22082541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
